Company:  ACCELERON PHARMA INC (XLRN)
Form Type:  DEF 14A
Filing Date:  4/16/2020 
CIK:  0001280600 
Address:  128 SIDNEY STREET 
City, State, Zip:  CAMBRIDGE, Massachusetts 02139 
Telephone:  617-649-9200 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$92.88  
Change: 
-2.74 (-2.87%)  
Trade Time: 
Aug 11  
Market Cap: 
$5.56B
Trade XLRN now with 

© 2020  
Description of Business
We are a biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Our research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta, or TGF-beta, protein superfamily. By combining our discovery and development expertise, including our proprietary knowledge of the TGF-beta superfamily, and our internal protein engineering and manufacturing capabilities, we have generated several innovative therapeutic candidates, all of which encompass novel potential first-in-class mechanisms of action. If successful, these candidates could have the potential to significantly improve clinical outcomes for patients across these areas of high, unmet need. We have focused and prioritized our research and development activities within three key therapeutic areas: hematology, pulmonary and neuromuscular. Hematology In November 2019, the U.S.
Register and access this filing in:     
  FORM DEF 14A
    NOTICE OF 2020 ANNUAL MEETING OF STOCKHOLDERS
    PROXY STATEMENT FOR 2020 ANNUAL MEETING OF STOCKHOLDERS
    SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
      BENEFICIAL OWNERS
      NAME AND TITLE
      NAME AND TITLE
      NAME AND TITLE
      COMPENSATION TABLE
      OPTIONS
      NAME AND TITLE
    COMPENSATION COMMITTEE REPORT
    EXECUTIVE OFFICER AND DIRECTOR COMPENSATION
      OPTIONS AGGREGATE
    AUDIT COMMITTEE REPORT
    CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
    PROPOSAL NO. 1-ELECTION OF DIRECTORS
    PROPOSAL NO. 2-ADVISORY VOTE ON EXECUTIVE COMPENSATION
    PROPOSAL NO. 3-RATIFICATION OF SELECTION OF INDEPENDENT ...